{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T03:55:41Z","timestamp":1777953341283,"version":"3.51.4"},"reference-count":127,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100007129","name":"Natural Science Foundation of Shandong Province","doi-asserted-by":"publisher","award":["ZR2022MC053"],"award-info":[{"award-number":["ZR2022MC053"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Young experts of Taishan Scholars","award":["tsqn202211380"],"award-info":[{"award-number":["tsqn202211380"]}]},{"name":"Health Science and Technology Innovation Team Construction Project of Shandong Province"},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2023M741864"],"award-info":[{"award-number":["2023M741864"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch. Pharm. Res."],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s12272-026-01612-1","type":"journal-article","created":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T07:22:52Z","timestamp":1776324172000},"page":"475-499","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Unraveling regorafenib resistance: metabolic reprogramming, tumor plasticity, and novel approaches to overcome therapy failure"],"prefix":"10.1007","volume":"49","author":[{"given":"Xiaokun","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuling","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Di","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yani","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuxuan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1982-8970","authenticated-orcid":false,"given":"Tao","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1895-4983","authenticated-orcid":false,"given":"Ning","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,4,16]]},"reference":[{"key":"1612_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-34889-z","volume":"13","author":"SJ Adua","year":"2022","unstructured":"Adua SJ, Arnal-Estap\u00e9 A, Zhao M, Qi B, Liu ZZ, Kravitz C, Hulme H, Strittmatter N, L\u00f3pez-Gir\u00e1ldez F, Chande S, Albert AE, Melnick M-A, Hu B, Politi K, Chiang V, Colclough N, Goodwin RJA, Cross D, Smith P, Nguyen DX (2022) Brain metastatic outgrowth and osimertinib resistance are potentiated by RhoA in EGFR-mutant lung cancer. Nat Commun 13:7690. https:\/\/doi.org\/10.1038\/s41467-022-34889-z","journal-title":"Nat Commun"},{"key":"1612_CR2","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2025.1631116","volume":"13","author":"G Agostini","year":"2025","unstructured":"Agostini G, Leprovots M, Jeandriens J, Lefort A, Libert F, Sclafani F, Langer I, Hendlisz A, Garcia M-I (2025) Autophagy inhibition improves sensitivity to the multi-kinase inhibitor regorafenib in preclinical mouse colon tumoroids. Front Cell Dev Biol 13:1631116. https:\/\/doi.org\/10.3389\/fcell.2025.1631116","journal-title":"Front Cell Dev Biol"},{"key":"1612_CR3","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/j.jhep.2020.11.008","volume":"74","author":"M Arechederra","year":"2021","unstructured":"Arechederra M, Bazai SK, Abdouni A, Sequera C, Mead TJ, Richelme S, Daian F, Audebert S, Dono R, Lozano A, Gregoire D, Hibner U, Allende DS, Apte SS, Maina F (2021) ADAMTSL5 is an epigenetically activated gene underlying tumorigenesis and drug resistance in hepatocellular carcinoma. J Hepatol 74:893\u2013906. https:\/\/doi.org\/10.1016\/j.jhep.2020.11.008","journal-title":"J Hepatol"},{"key":"1612_CR4","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v32.i3.111528","author":"S Ascari","year":"2026","unstructured":"Ascari S, Chen R, De Sinno A, Stefanini B, Cescon M, Serenari M, Mosconi C, Tovoli F (2026) Post-immunotherapy second-line strategies for hepatocellular carcinoma: State of the art and ongoing trials. World J Gastroenterol. https:\/\/doi.org\/10.3748\/wjg.v32.i3.111528","journal-title":"World J Gastroenterol"},{"key":"1612_CR5","doi-asserted-by":"publisher","DOI":"10.20517\/cdr.2023.33","author":"S Astore","year":"2023","unstructured":"Astore S, Baciarello G, Cerbone L, Calabr\u00f2 F (2023) Primary and acquired resistance to first-line therapy for clear cell renal cell carcinoma. Cancer Drug Resist. https:\/\/doi.org\/10.20517\/cdr.2023.33","journal-title":"Cancer Drug Resist"},{"key":"1612_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21071-0","volume":"12","author":"H Bai","year":"2021","unstructured":"Bai H, Wang J, Phan CU, Chen Q, Hu X, Shao G, Zhou J, Lai L, Tang G (2021) Cyclodextrin-based host-guest complexes loaded with regorafenib for colorectal cancer treatment. Nat Commun 12:759. https:\/\/doi.org\/10.1038\/s41467-021-21071-0","journal-title":"Nat Commun"},{"key":"1612_CR7","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1080\/17435889.2024.2434452","volume":"20","author":"L Battaglia","year":"2025","unstructured":"Battaglia L, Dianzani C, Muntoni E, Marini E, Bozza A, Bordano V, Ferraris C, Garelli S, Valsania MC, Terreno E, Capozza M, Costanzo D, Capucchio MT, Hassan T, Pizzimenti S, Pettineo E, Di Muro M, Scorziello F (2025) Ultrasmall solid lipid nanoparticles as a potential innovative delivery system for a drug combination against glioma. Nanomedicine 20:37\u201352. https:\/\/doi.org\/10.1080\/17435889.2024.2434452","journal-title":"Nanomedicine"},{"key":"1612_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16173103","volume":"16","author":"S Boichuk","year":"2024","unstructured":"Boichuk S, Dunaev P, Galembikova A, Valeeva E (2024) Fibroblast growth factor 2 (FGF2) activates vascular endothelial growth factor (VEGF) signaling in gastrointestinal stromal tumors (GIST): an autocrine mechanism contributing to imatinib mesylate (IM) resistance. Cancers 16:3103. https:\/\/doi.org\/10.3390\/cancers16173103","journal-title":"Cancers"},{"key":"1612_CR9","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1238883","volume":"13","author":"K Breitenecker","year":"2023","unstructured":"Breitenecker K, Hedrich V, Pupp F, Chen D, \u0158ezn\u00ed\u010dkov\u00e1 E, Ortmayr G, Huber H, Weber G, Balcar L, Pinter M, Mikulits W (2023) Synergism of the receptor tyrosine kinase Axl with ErbB receptors mediates resistance to regorafenib in hepatocellular carcinoma. Front Oncol 13:1238883. https:\/\/doi.org\/10.3389\/fonc.2023.1238883","journal-title":"Front Oncol"},{"key":"1612_CR10","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-018-0836-x","volume":"37","author":"M-H Cai","year":"2018","unstructured":"Cai M-H, Xu X-G, Yan S-L, Sun Z, Ying Y, Wang B-K, Tu Y-X (2018) Regorafenib suppresses colon tumorigenesis and the generation of drug resistant cancer stem-like cells via modulation of miR-34a associated signaling. J Exp Clin Cancer Res 37:151. https:\/\/doi.org\/10.1186\/s13046-018-0836-x","journal-title":"J Exp Clin Cancer Res"},{"key":"1612_CR11","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1186\/s12876-022-02344-4","volume":"22","author":"G Cao","year":"2022","unstructured":"Cao G, Wang X, Chen H, Gao S, Guo J, Liu P, Xu H, Xu L, Zhu X, Yang R (2022) Hepatic arterial infusion chemotherapy plus regorafenib in advanced colorectal cancer: a real-world retrospective study. BMC Gastroenterol 22:328. https:\/\/doi.org\/10.1186\/s12876-022-02344-4","journal-title":"BMC Gastroenterol"},{"key":"1612_CR12","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1002\/2211-5463.12578","volume":"9","author":"W Chen","year":"2019","unstructured":"Chen W, Yang J, Zhang Y, Cai H, Chen X, Sun D (2019) Regorafenib reverses HGF -induced sorafenib resistance by inhibiting epithelial-mesenchymal transition in hepatocellular carcinoma. FEBS Open Bio 9:335\u2013347. https:\/\/doi.org\/10.1002\/2211-5463.12578","journal-title":"FEBS Open Bio"},{"key":"1612_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexcr.2020.112060","volume":"393","author":"J Chen","year":"2020","unstructured":"Chen J, Dai J, Kang Z, Yang T, Zhao Q, Zheng J, Zhang X, Zhang J, Xu J, Sun G, Yang L, Yang T (2020) A combinatorial strategy for overcoming primary and acquired resistance of MEK inhibition in colorectal cancer. Exp Cell Res 393:112060. https:\/\/doi.org\/10.1016\/j.yexcr.2020.112060","journal-title":"Exp Cell Res"},{"key":"1612_CR14","doi-asserted-by":"publisher","DOI":"10.3892\/etm.2022.11132","volume":"23","author":"Z-Y Chen","year":"2022","unstructured":"Chen Z-Y, Li J, Zhu S-D, Li Z-D, Yu J-L, Wu J, Zhang C, Zeng L-H (2022) Harmine reinforces the effects of regorafenib on suppressing cell proliferation and inducing apoptosis in liver cancer cells. Exp Ther Med 23:209. https:\/\/doi.org\/10.3892\/etm.2022.11132","journal-title":"Exp Ther Med"},{"key":"1612_CR15","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-024-01647-1","volume":"17","author":"Y Chen","year":"2024","unstructured":"Chen Y, Dai S, Cheng C, Chen L (2024) Lenvatinib and immune-checkpoint inhibitors in hepatocellular carcinoma: mechanistic insights, clinical efficacy, and future perspectives. J Hematol Oncol 17:130. https:\/\/doi.org\/10.1186\/s13045-024-01647-1","journal-title":"J Hematol Oncol"},{"key":"1612_CR16","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1016\/j.hbpd.2025.09.004","volume":"24","author":"Y Cheng","year":"2025","unstructured":"Cheng Y, Wang J-Y, Lu Y, Xia Y-X, Zhao H, Wang Q, Zhu X-L, Zu Q-Q, Li H-K, Chen Z, Li X-C (2025) Efficacy of regorafenib following first-line immune checkpoint inhibitor failure in patients with advanced hepatocellular carcinoma: a multicenter study. Hepatobiliary Pancreat Dis Int 24:656\u2013665. https:\/\/doi.org\/10.1016\/j.hbpd.2025.09.004","journal-title":"Hepatobiliary Pancreat Dis Int"},{"key":"1612_CR17","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.annonc.2025.10.002","volume":"37","author":"P Cirac\u00ec","year":"2026","unstructured":"Cirac\u00ec P, Germani MM, Pietrantonio F, Manca P, Lonardi S, Busico A, Bergamo F, Burgio V, Mannavola F, Di Donato S, Fenocchio E, Palermo F, Capone I, De Grandis MC, Pella N, Scartozzi M, Antonuzzo L, Passardi A, Claravezza M, Salvatore L, Tamberi S, Randon G, Conca E, Conca V, Antoniotti C, Moretto R, Masi G, Boni L, Rossini D, Cremolini C, Formica V, Martignetti A, Corsi DC, Fea E, Parlagreco E, Gennari A, Berardi R, Simionato F, Sperti E, Pastorino A, Baldini E, Dell\u2019Aquila E, Tamburini E, Zucchelli G, Buonadonna A, Chiari R, Cinieri S, Ballestrero A, Berenato R, Paris MK, Cupini S, Ghidini M, Frisinghelli M, Sonaglio C (2026) Re-treatment with panitumumab followed by regorafenib versus the reverse sequence in chemorefractory metastatic colorectal cancer patients with RAS and BRAF wild-type circulating tumor DNA: the PARERE study by GONO. Ann Oncol 37:79\u201391. https:\/\/doi.org\/10.1016\/j.annonc.2025.10.002","journal-title":"Ann Oncol"},{"key":"1612_CR18","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1016\/S1470-2045(23)00358-3","volume":"24","author":"SL Cytryn","year":"2023","unstructured":"Cytryn SL, Moy RH, Cowzer D, Shah RH, Chou JF, Joshi SS, Ku GY, Maron SB, Desai A, Yang J, Sugarman R, Rao D, Goldberg Z, Charalambous C, Lapshina M, Antoine A, Socolow F, Trivedi N, Capanu M, Gerdes H, Schattner MA, Simmons M, Lacouture ME, Paroder V, Tang LH, Shia J, Ilson DH, Solit DB, Berger MF, Janjigian YY (2023) First-line regorafenib with nivolumab and chemotherapy in advanced oesophageal, gastric, or gastro-oesophageal junction cancer in the USA: a single-arm, single-centre, phase 2 trial. Lancet Oncol 24:1073\u20131082. https:\/\/doi.org\/10.1016\/S1470-2045(23)00358-3","journal-title":"Lancet Oncol"},{"key":"1612_CR19","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.canlet.2021.10.024","volume":"524","author":"Z Dai","year":"2022","unstructured":"Dai Z, Wang X, Peng R, Zhang B, Han Q, Lin J, Wang J, Lin J, Jiang M, Liu H, Lee TH, Lu KP, Zheng M (2022) Induction of IL-6R\u03b1 by ATF3 enhances IL-6 mediated sorafenib and regorafenib resistance in hepatocellular carcinoma. Cancer Lett 524:161\u2013171. https:\/\/doi.org\/10.1016\/j.canlet.2021.10.024","journal-title":"Cancer Lett"},{"key":"1612_CR20","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1038\/s41416-023-02389-6","volume":"129","author":"MJ Egidi","year":"2023","unstructured":"Egidi MJ, Krug S, Haybaeck J, Michl P, Griesmann H (2023) Anti-angiogenic therapy using the multi-tyrosine kinase inhibitor regorafenib enhances tumor progression in a transgenic mouse model of \u00df-cell carcinogenesis. Br J Cancer 129:1225\u20131237. https:\/\/doi.org\/10.1038\/s41416-023-02389-6","journal-title":"Br J Cancer"},{"key":"1612_CR21","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000001585","author":"AB El-Khoueiry","year":"2025","unstructured":"El-Khoueiry AB, Kim RD, Harris WP, Sung MW, Waldschmidt D, Cabrera R, Garosi VL, Ploeger BA, Zebger-Gong H, Brennan BJ, Wang YA, Mueller U, Weispfenning A, Seidel H, Coppieters S, Ishida TC, Galle PR (2025) A multicenter dose-defining\/expansion phase 1b study of first-line regorafenib plus pembrolizumab in patients with advanced hepatocellular carcinoma. Hepatology. https:\/\/doi.org\/10.1097\/HEP.0000000000001585","journal-title":"Hepatology"},{"key":"1612_CR22","doi-asserted-by":"publisher","first-page":"64136","DOI":"10.18632\/oncotarget.11636","volume":"7","author":"L-C Fan","year":"2016","unstructured":"Fan L-C, Teng H-W, Shiau C-W, Tai W-T, Hung M-H, Yang S-H, Jiang J-K, Chen K-F (2016) Regorafenib (Stivarga) pharmacologically targets epithelial-mesenchymal transition in colorectal cancer. Oncotarget 7:64136\u201364147. https:\/\/doi.org\/10.18632\/oncotarget.11636","journal-title":"Oncotarget"},{"key":"1612_CR23","doi-asserted-by":"publisher","first-page":"2632","DOI":"10.1016\/j.xphs.2017.04.064","volume":"106","author":"K Fujita","year":"2017","unstructured":"Fujita K, Masuo Y, Yamazaki E, Shibutani T, Kubota Y, Nakamichi N, Sasaki Y, Kato Y (2017) Involvement of the transporters P-glycoprotein and breast cancer resistance protein in dermal distribution of the multikinase inhibitor regorafenib and its active metabolites. J Pharm Sci 106:2632\u20132641. https:\/\/doi.org\/10.1016\/j.xphs.2017.04.064","journal-title":"J Pharm Sci"},{"key":"1612_CR24","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/s00280-017-3480-9","volume":"81","author":"M Gerisch","year":"2018","unstructured":"Gerisch M, Hafner F-T, Lang D, Radtke M, Diefenbach K, Cleton A, Lettieri J (2018) Mass balance, metabolic disposition, and pharmacokinetics of a single oral dose of Regorafenib in healthy human subjects. Cancer Chemother Pharmacol 81:195\u2013206. https:\/\/doi.org\/10.1007\/s00280-017-3480-9","journal-title":"Cancer Chemother Pharmacol"},{"key":"1612_CR25","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1007\/s00066-023-02172-9","volume":"200","author":"F Gregucci","year":"2024","unstructured":"Gregucci F, Di Guglielmo FC, Surgo A, Carbonara R, Laera L, Ciliberti MP, Gentile MA, Calbi R, Caliandro M, Sasso N, Davi\u2019 V, Bonaparte I, Fanelli V, Giraldi D, Tortora R, Intern\u00f2 V, Giuliani F, Surico G, Signorelli F, Lombardi G, Fiorentino A (2024) Reirradiation with radiosurgery or stereotactic fractionated radiotherapy in association with regorafenib in recurrent glioblastoma. Strahlenther Onkol 200:751\u2013759. https:\/\/doi.org\/10.1007\/s00066-023-02172-9","journal-title":"Strahlenther Onkol"},{"key":"1612_CR26","doi-asserted-by":"publisher","DOI":"10.1186\/s40001-023-01099-2","volume":"28","author":"S Gr\u00fcnewald","year":"2023","unstructured":"Gr\u00fcnewald S, Stecklum M, Rizzo M, Rathjens J, Fiebig L, Zopf D (2023) Effects of regorafenib on the mononuclear\/phagocyte system and how these contribute to the inhibition of colorectal tumors in mice. Eur J Med Res 28:147. https:\/\/doi.org\/10.1186\/s40001-023-01099-2","journal-title":"Eur J Med Res"},{"key":"1612_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2022.166431","volume":"1868","author":"R Gundamaraju","year":"2022","unstructured":"Gundamaraju R, Lu W, Paul MK, Jha NK, Gupta PK, Ojha S, Chattopadhyay I, Rao PV, Ghavami S (2022) Autophagy and EMT in cancer and metastasis: who controls whom? Biochimica Et Biophysica Acta (BBA): Mole Basis Dis 1868:166431. https:\/\/doi.org\/10.1016\/j.bbadis.2022.166431","journal-title":"Biochimica Et Biophysica Acta (BBA): Mole Basis Dis"},{"key":"1612_CR28","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1016\/j.sjbs.2021.10.019","volume":"29","author":"Y Guo","year":"2022","unstructured":"Guo Y, Mehrabi Nasab E, Hassanpour F, Athari SS (2022) Linsitinib and aspirin as the IGF1-R antagonists, inhibit Regorafenib-resistant chemotherapy in colon cancer. Saudi J Biol Sci 29:872\u2013877. https:\/\/doi.org\/10.1016\/j.sjbs.2021.10.019","journal-title":"Saudi J Biol Sci"},{"key":"1612_CR29","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1007\/s13346-023-01401-z","volume":"14","author":"U Hasan","year":"2024","unstructured":"Hasan U, Chauhan M, Basu SM, R. J, Giri J (2024) Overcoming multidrug resistance by reversan and exterminating glioblastoma and glioblastoma stem cells by delivering drug-loaded nanostructure hybrid lipid capsules (nHLCs). Drug Deliv Transl Res 14:342\u2013359. https:\/\/doi.org\/10.1007\/s13346-023-01401-z","journal-title":"Drug Deliv Transl Res"},{"key":"1612_CR30","doi-asserted-by":"publisher","first-page":"2140","DOI":"10.1158\/1078-0432.CCR-23-2748","volume":"30","author":"S Hedayat","year":"2024","unstructured":"Hedayat S, Cascione L, Cunningham D, Schirripa M, Lampis A, Hahne JC, Tunariu N, Hong SP, Marchetti S, Khan K, Fontana E, Angerilli V, Delrieux M, Nava Rodrigues D, Procaccio L, Rao S, Watkins D, Starling N, Chau I, Braconi C, Fotiadis N, Begum R, Guppy N, Howell L, Valenti M, Cribbes S, Kolozsvari B, Kirkin V, Lonardi S, Ghidini M, Passalacqua R, Elghadi R, Magnani L, Pinato DJ, Di Maggio F, Ghelardi F, Sottotetti E, Vetere G, Cirac\u00ec P, Vlachogiannis G, Pietrantonio F, Cremolini C, Cortellini A, Loupakis F, Fassan M, Valeri N (2024) Circulating microRNA analysis in a prospective co-clinical trial identifies MIR652\u20133p as a response biomarker and driver of Regorafenib resistance mechanisms in colorectal cancer. Clin Cancer Res 30:2140\u20132159. https:\/\/doi.org\/10.1158\/1078-0432.CCR-23-2748","journal-title":"Clin Cancer Res"},{"key":"1612_CR31","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1007\/s40265-018-0932-4","volume":"78","author":"Y-A Heo","year":"2018","unstructured":"Heo Y-A, Syed YY (2018) Regorafenib: a review in hepatocellular carcinoma. Drugs 78:951\u2013958. https:\/\/doi.org\/10.1007\/s40265-018-0932-4","journal-title":"Drugs"},{"key":"1612_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2023.115812","volume":"217","author":"E Herraez","year":"2023","unstructured":"Herraez E, Al-Abdulla R, Soto M, Briz O, Bettinger D, Bantel H, Del Carmen S, Serrano MA, Geier A, Marin JJG, Macias RIR (2023) Role of organic cation transporter 3 (OCT3) in the response of hepatocellular carcinoma to tyrosine kinase inhibitors. Biochem Pharmacol 217:115812. https:\/\/doi.org\/10.1016\/j.bcp.2023.115812","journal-title":"Biochem Pharmacol"},{"key":"1612_CR33","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2024.1464610","volume":"11","author":"L Hu","year":"2024","unstructured":"Hu L, Shi W, Liu K, Ma D, Xin Q, Wang Z, Cao Y, Zhang G (2024) EGFR bypass activation mediates acquired resistance to Regorafenib in hepatocellular carcinoma. Front Med 11:1464610. https:\/\/doi.org\/10.3389\/fmed.2024.1464610","journal-title":"Front Med"},{"key":"1612_CR34","doi-asserted-by":"publisher","first-page":"3498","DOI":"10.1158\/0008-5472.CAN-23-2921","volume":"83","author":"MH Hung","year":"2023","unstructured":"Hung MH, Wang XW (2023) Targeting WNT\/\u03b2-Catenin via modulating EZH2 function: a new chapter in the treatment of \u03b2-Catenin mutant hepatocellular carcinoma? Cancer Res 83:3498\u20133500. https:\/\/doi.org\/10.1158\/0008-5472.CAN-23-2921","journal-title":"Cancer Res"},{"key":"1612_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-020-00264-x","volume":"5","author":"A Huang","year":"2020","unstructured":"Huang A, Yang X-R, Chung W-Y, Dennison AR, Zhou J (2020) Targeted therapy for hepatocellular carcinoma. Sig Transduct Target Ther 5:146. https:\/\/doi.org\/10.1038\/s41392-020-00264-x","journal-title":"Sig Transduct Target Ther"},{"key":"1612_CR36","doi-asserted-by":"publisher","first-page":"3429","DOI":"10.1111\/jgh.15619","volume":"36","author":"H Huang","year":"2021","unstructured":"Huang H, Hou J, Liu K, Liu Q, Shen L, Liu B, Lu Q, Zhang N, Che L, Li J, Jiang S, Wang B, Wen Q, Hu L, Gao J (2021) RAB27A-dependent release of exosomes by liver cancer stem cells induces Nanog expression in their differentiated progenies and confers Regorafenib resistance. J Gastroenterol Hepatol 36:3429\u20133437. https:\/\/doi.org\/10.1111\/jgh.15619","journal-title":"J Gastroenterol Hepatol"},{"key":"1612_CR37","doi-asserted-by":"publisher","first-page":"157","DOI":"10.2147\/JHC.S353956","volume":"9","author":"J Huang","year":"2022","unstructured":"Huang J, Guo Y, Huang W, Hong X, Quan Y, Lin L, Zhou J, Liang L, Zhang Y, Zhou J, Cai M, Zhu K (2022) Regorafenib combined with PD-1 blockade immunotherapy versus Regorafenib as second-line treatment for advanced hepatocellular carcinoma: a multicenter retrospective study. J Histochem Cytochem 9:157\u2013170. https:\/\/doi.org\/10.2147\/JHC.S353956","journal-title":"J Histochem Cytochem"},{"key":"1612_CR38","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19041232","volume":"19","author":"Y Itatani","year":"2018","unstructured":"Itatani Y, Kawada K, Yamamoto T, Sakai Y (2018) Resistance to anti-angiogenic therapy in cancer\u2014alterations to anti-VEGF pathway. Int J Mol Sci 19:1232. https:\/\/doi.org\/10.3390\/ijms19041232","journal-title":"Int J Mol Sci"},{"key":"1612_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2025.189494","volume":"1880","author":"R Izadpanah","year":"2025","unstructured":"Izadpanah R, Izadpanah A, Alt EU (2025) Dual faces of angiogenesis: mechanisms and therapeutic applications. Biochimica Et Biophysica Acta (BBA) - Reviews on Cancer 1880:189494. https:\/\/doi.org\/10.1016\/j.bbcan.2025.189494","journal-title":"Biochimica Et Biophysica Acta (BBA) - Reviews on Cancer"},{"key":"1612_CR40","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1146\/annurev-biochem-052521-040754","volume":"93","author":"H Jeon","year":"2024","unstructured":"Jeon H, Tkacik E, Eck MJ (2024) Signaling from RAS to RAF: the molecules and their mechanisms. Annu Rev Biochem 93:289\u2013316. https:\/\/doi.org\/10.1146\/annurev-biochem-052521-040754","journal-title":"Annu Rev Biochem"},{"key":"1612_CR41","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1080\/15548627.2019.1598752","volume":"16","author":"J Jiang","year":"2020","unstructured":"Jiang J, Zhang L, Chen H, Lei Y, Zhang T, Wang Y, Jin P, Lan J, Zhou L, Huang Z, Li B, Liu Y, Gao W, Xie K, Zhou L, Nice EC, Peng Y, Cao Y, Wei Y, Wang K, Huang C (2020) Regorafenib induces lethal autophagy arrest by stabilizing PSAT1 in glioblastoma. Autophagy 16:106\u2013122. https:\/\/doi.org\/10.1080\/15548627.2019.1598752","journal-title":"Autophagy"},{"key":"1612_CR42","doi-asserted-by":"publisher","first-page":"861","DOI":"10.4149\/neo_2021_201228N1415","volume":"68","author":"F-E Jiang","year":"2021","unstructured":"Jiang F-E, Zhang H-J, Yu C-Y, Liu A-N (2021) Efficacy and safety of Regorafenib or fruquintinib plus camrelizumab in patients with microsatellite stable and\/or proficient mismatch repair metastatic colorectal cancer: an observational pilot study. Neo 68:861\u2013866. https:\/\/doi.org\/10.4149\/neo_2021_201228N1415","journal-title":"Neo"},{"key":"1612_CR43","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1007\/s12672-024-01572-2","volume":"15","author":"Y Jin","year":"2024","unstructured":"Jin Y, Liu Q, Sun B, Li X, Wu J, Lin Z, Ma Y, Jia H (2024) Pralatrexate represses the resistance of HCC cells to molecular targeted agents via the miRNA-34a\/Notch pathway. Discov Onc 15:709. https:\/\/doi.org\/10.1007\/s12672-024-01572-2","journal-title":"Discov Onc"},{"key":"1612_CR44","doi-asserted-by":"publisher","DOI":"10.3390\/jcm15010317","volume":"15","author":"P Kawczak","year":"2026","unstructured":"Kawczak P, B\u0105czek T (2026) The evolving role of second- and third-generation tyrosine kinase inhibitors in gastrointestinal malignancies: advances in targeted therapy with sunitinib, Regorafenib, and avapritinib. J Clin Microbiol 15:317. https:\/\/doi.org\/10.3390\/jcm15010317","journal-title":"J Clin Microbiol"},{"key":"1612_CR45","doi-asserted-by":"publisher","DOI":"10.3390\/cells11223663","volume":"11","author":"P Kehagias","year":"2022","unstructured":"Kehagias P, Kindt N, Krayem M, Najem A, Agostini G, Acedo Reina E, Bregni G, Sclafani F, Journe F, Awada A, Ghanem GE, Hendlisz A (2022) Regorafenib induces senescence and epithelial-mesenchymal transition in colorectal cancer to promote drug resistance. Cells 11:3663. https:\/\/doi.org\/10.3390\/cells11223663","journal-title":"Cells"},{"key":"1612_CR46","doi-asserted-by":"publisher","first-page":"2362","DOI":"10.1111\/bcp.14334","volume":"86","author":"A Keunecke","year":"2020","unstructured":"Keunecke A, Hoefman S, Drenth H, Zisowsky J, Cleton A, Ploeger BA (2020) Population pharmacokinetics of Regorafenib in solid tumours: exposure in clinical practice considering enterohepatic circulation and food intake. Br J Clin Pharmacol 86:2362\u20132376. https:\/\/doi.org\/10.1111\/bcp.14334","journal-title":"Br J Clin Pharmacol"},{"key":"1612_CR47","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1158\/1535-7163.MCT-15-0847","volume":"15","author":"J Kim","year":"2016","unstructured":"Kim J, Ulu A, Wan D, Yang J, Hammock BD, Weiss RH (2016) Addition of DHA synergistically enhances the efficacy of regorafenib for kidney cancer therapy. Mol Cancer Ther 15:890\u2013898. https:\/\/doi.org\/10.1158\/1535-7163.MCT-15-0847","journal-title":"Mol Cancer Ther"},{"key":"1612_CR48","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1038\/s41591-024-02824-y","volume":"30","author":"H-D Kim","year":"2024","unstructured":"Kim H-D, Jung S, Lim HY, Ryoo B-Y, Ryu M-H, Chuah S, Chon HJ, Kang B, Hong JY, Lee HC, Moon D-B, Kim K-H, Kim TW, Tai D, Chew V, Lee JS, Finn RS, Koh J-Y, Yoo C (2024) Regorafenib plus nivolumab in unresectable hepatocellular carcinoma: the phase 2 RENOBATE trial. Nat Med 30:699\u2013707. https:\/\/doi.org\/10.1038\/s41591-024-02824-y","journal-title":"Nat Med"},{"key":"1612_CR49","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1002\/mc.23769","volume":"63","author":"S Kuang","year":"2024","unstructured":"Kuang S, Zhang J, Huang N, Zhang J, Chen B, Wang L, Liu M (2024) The cumulative antitumor effects of regorafenib and radiotherapy in hepatocellular carcinoma. Mol Carcinog 63:1738\u20131749. https:\/\/doi.org\/10.1002\/mc.23769","journal-title":"Mol Carcinog"},{"key":"1612_CR50","doi-asserted-by":"publisher","DOI":"10.1016\/j.jceh.2025.102547","volume":"15","author":"K Kumar","year":"2025","unstructured":"Kumar K, Saraswat VA (2025) Evolving landscape of systemic therapy for hepatocellular carcinoma in 2025. J Clin Exp Hepatol 15:102547. https:\/\/doi.org\/10.1016\/j.jceh.2025.102547","journal-title":"J Clin Exp Hepatol"},{"key":"1612_CR51","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000237","author":"AD Ladd","year":"2023","unstructured":"Ladd AD, Duarte S, Sahin I, Zarrinpar A (2023) Mechanisms of drug resistance in HCC. Hepatology. https:\/\/doi.org\/10.1097\/HEP.0000000000000237","journal-title":"Hepatology"},{"key":"1612_CR52","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1093\/jpp\/rgad034","volume":"75","author":"J Li","year":"2023","unstructured":"Li J, Hua Q (2023) Regorafenib inhibits growth, survival and angiogenesis in nasopharyngeal carcinoma and is synergistic with Mcl-1 inhibitor. J Pharm Pharmacol 75:1177\u20131185. https:\/\/doi.org\/10.1093\/jpp\/rgad034","journal-title":"J Pharm Pharmacol"},{"key":"1612_CR53","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202200449","volume":"34","author":"Z Li","year":"2022","unstructured":"Li Z, Xu W, Yang J, Wang J, Wang J, Zhu G, Li D, Ding J, Sun T (2022) A tumor microenvironments\u2010adapted polypeptide hydrogel\/nanogel composite boosts antitumor molecularly targeted inhibition and immunoactivation. Adv Mater 34:2200449. https:\/\/doi.org\/10.1002\/adma.202200449","journal-title":"Adv Mater"},{"key":"1612_CR54","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-025-01135-w","volume":"9","author":"X Liang","year":"2025","unstructured":"Liang X, Xu J, Shu S, Lv W, Yin D, Miao S, Lu X, Zhang C, Liu X, Dai J, Li J, Wu W, Zhang E, Guo R (2025) GLMP promotes EGFR-TKI resistance by activating autophagy and RhoA pathway in non-small cell lung cancer. Npj Precis Onc 9:391. https:\/\/doi.org\/10.1038\/s41698-025-01135-w","journal-title":"Npj Precis Onc"},{"key":"1612_CR55","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-025-04202-7","author":"S Liang","year":"2026","unstructured":"Liang S, Zheng D, Chu T, Yang D, Zhang K, Yang L, Yang Y, Ma W (2026) Synergistic mechanisms and clinical translation of regorafenib combination therapies. Clin Transl Oncol. https:\/\/doi.org\/10.1007\/s12094-025-04202-7","journal-title":"Clin Transl Oncol"},{"key":"1612_CR56","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-024-05545-5","volume":"22","author":"S Liao","year":"2024","unstructured":"Liao S, Wang Q, Chen S, Huang Q, Zhou L, Liu H, He S, Zhou Z (2024) Mito-LND and (E)-Akt inhibitor-IV: novel compounds inducing endoplasmic reticulum stress and ROS accumulation against hepatocellular carcinoma. J Transl Med 22:792. https:\/\/doi.org\/10.1186\/s12967-024-05545-5","journal-title":"J Transl Med"},{"key":"1612_CR57","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-015-0210-1","volume":"34","author":"C Lippolis","year":"2015","unstructured":"Lippolis C, Refolo MG, D\u2019Alessandro R, Carella N, Messa C, Cavallini A, Carr BI (2015) Resistance to multikinase inhibitor actions mediated by insulin like growth factor-1. J Exp Clin Cancer Res 34:90. https:\/\/doi.org\/10.1186\/s13046-015-0210-1","journal-title":"J Exp Clin Cancer Res"},{"key":"1612_CR58","doi-asserted-by":"publisher","first-page":"3217","DOI":"10.21873\/invivo.12157","volume":"34","author":"Y-C Liu","year":"2020","unstructured":"Liu Y-C, Chiang I-T, Chung J-G, Hsieh J-H, Chiang C-H, Weng M-C, Hsu F-T, Lee Y-H, Chang C-S, Lin S-S (2020) Therapeutic efficacy and inhibitory mechanism of regorafenib combined with radiation in colorectal cancer. In Vivo 34:3217\u20133224. https:\/\/doi.org\/10.21873\/invivo.12157","journal-title":"In Vivo"},{"key":"1612_CR59","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202402327","volume":"11","author":"K Liu","year":"2024","unstructured":"Liu K, Tian F, Chen X, Liu B, Tian S, Hou Y, Wang L, Han M, Peng S, Tan Y, Pan Y, Chu Z, Li J, Che L, Chen D, Wen L, Qin Z, Li X, Xiang J, Bian X, Liu Q, Ye X, Wang T, Wang B (2024) Stabilization of TGF\u2010\u03b2 receptor 1 by a receptor\u2010associated adaptor dictates feedback activation of the TGF\u2010\u03b2 signaling pathway to maintain liver cancer stemness and drug resistance. Adv Sci 11:2402327. https:\/\/doi.org\/10.1002\/advs.202402327","journal-title":"Adv Sci"},{"key":"1612_CR60","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-56748-3","volume":"16","author":"R Liu","year":"2025","unstructured":"Liu R, Ji Z, Wang X, Zhu L, Xin J, Ma L, Zhang J, Ge S, Zhang L, Yang Y, Ning T, Bai M, Duan J, Wang F, Sun Y, Li H, Deng T, Ba Y, Hao J (2025) Regorafenib plus sintilimab as a salvage treatment for microsatellite stable metastatic colorectal cancer: a single-arm, open-label, phase II clinical trial. Nat Commun 16:1481. https:\/\/doi.org\/10.1038\/s41467-025-56748-3","journal-title":"Nat Commun"},{"key":"1612_CR61","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1186\/s12916-023-03066-4","volume":"21","author":"X Lu","year":"2023","unstructured":"Lu X, Liu R, Liao Y, Cui L, Sun H, Zhang D, Wang B, Fang L, Guan X, Yao Y, Liu C, Zhang Y (2023) ACVRL1 drives resistance to multitarget tyrosine kinase inhibitors in colorectal cancer by promoting USP15-mediated GPX2 stabilization. BMC Med 21:366. https:\/\/doi.org\/10.1186\/s12916-023-03066-4","journal-title":"BMC Med"},{"key":"1612_CR62","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.29894","volume":"96","author":"Z Lv","year":"2024","unstructured":"Lv Z, Liu L, You J, Zhou P, Su Y, Zhao K, Zhang J, Zhu F (2024) Small HBV surface antigen drives regorafenib resistance in HCC via KIAA1429-dependent m6A modification of CCR9. J Med Virol 96:e29894. https:\/\/doi.org\/10.1002\/jmv.29894","journal-title":"J Med Virol"},{"key":"1612_CR63","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1016\/j.tranon.2018.12.003","volume":"12","author":"C-J Ma","year":"2019","unstructured":"Ma C-J, Huang C-W, Chang T-K, Tsai H-L, Su W-C, Yeh Y-S, Chen P-J, Wang J-Y (2019) Oncologic outcomes in metastatic colorectal cancer with regorafenib with FOLFIRI as a third- or fourth-line setting. Transl Oncol 12:502\u2013512. https:\/\/doi.org\/10.1016\/j.tranon.2018.12.003","journal-title":"Transl Oncol"},{"key":"1612_CR64","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1080\/14712598.2020.1677603","volume":"20","author":"T Macarulla","year":"2020","unstructured":"Macarulla T, Montagut C, S\u00e1nchez-Martin FJ, Granja M, Verdaguer H, Sastre J, Tabernero J (2020) The role of PIGF blockade in the treatment of colorectal cancer: overcoming the pitfalls. Expert Opin Biol Ther 20:15\u201322. https:\/\/doi.org\/10.1080\/14712598.2020.1677603","journal-title":"Expert Opin Biol Ther"},{"key":"1612_CR65","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19102915","volume":"19","author":"K Matsuoka","year":"2018","unstructured":"Matsuoka K, Nakagawa F, Tanaka N, Okabe H, Matsuo K, Takechi T (2018) Effective sequential combined chemotherapy with trifluridine\/tipiracil and regorafenib in human colorectal cancer cells. Int J Mol Sci 19:2915. https:\/\/doi.org\/10.3390\/ijms19102915","journal-title":"Int J Mol Sci"},{"key":"1612_CR66","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1111\/cas.14273","volume":"111","author":"S Matsusaka","year":"2020","unstructured":"Matsusaka S, Hanna DL, Ning Y, Yang D, Cao S, Berger MD, Miyamoto Y, Suenaga M, Dan S, Mashima T, Seimiya H, Zhang W, Lenz H (2020) Epidermal growth factor receptor mRNA expression: a potential molecular escape mechanism from regorafenib. Cancer Sci 111:441\u2013450. https:\/\/doi.org\/10.1111\/cas.14273","journal-title":"Cancer Sci"},{"key":"1612_CR67","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1080\/09553002.2020.1730012","volume":"97","author":"M Mehta","year":"2021","unstructured":"Mehta M, Griffith J, Panneerselvam J, Babu A, Mani J, Herman T, Ramesh R, Munshi A (2021) Regorafenib sensitizes human breast cancer cells to radiation by inhibiting multiple kinases and inducing DNA damage. Int J Radiat Biol 97:1109\u20131120. https:\/\/doi.org\/10.1080\/09553002.2020.1730012","journal-title":"Int J Radiat Biol"},{"key":"1612_CR68","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1007\/s10637-021-01123-4","volume":"39","author":"F Meng","year":"2021","unstructured":"Meng F, Chen Y, Yang M, Zhang H, Wang W (2021) Concomitant inhibition of B7\u2013H3 and PD-L1 expression by a novel and synthetic microRNA delivers potent antitumor activities in colorectal tumor models. Invest New Drugs 39:1267\u20131274. https:\/\/doi.org\/10.1007\/s10637-021-01123-4","journal-title":"Invest New Drugs"},{"key":"1612_CR69","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.alcohol.2020.03.009","volume":"86","author":"V Mishra","year":"2020","unstructured":"Mishra V, Agas A, Schuetz H, Kalluru J, Haorah J (2020) Alcohol induces programmed death receptor-1 and programmed death-ligand-1 differentially in neuroimmune cells. Alcohol 86:65\u201374. https:\/\/doi.org\/10.1016\/j.alcohol.2020.03.009","journal-title":"Alcohol"},{"key":"1612_CR70","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2024.123165","volume":"358","author":"H Mu","year":"2024","unstructured":"Mu H, Hu J, Lin Z, Wei L, Li Q, Wang X, Geng P, Zhong R, Cui S, Liu W, Hu C, Xu G, Tan G (2024) Integration of network pharmacology, metabolomics and lipidomics for clarifying the role of sphingolipid metabolism in the treatment of liver cancer by regorafenib. Life Sci 358:123165. https:\/\/doi.org\/10.1016\/j.lfs.2024.123165","journal-title":"Life Sci"},{"key":"1612_CR71","doi-asserted-by":"publisher","DOI":"10.1016\/j.tice.2025.102876","volume":"95","author":"N Nakamura","year":"2025","unstructured":"Nakamura N, Tabata R, Tabata C (2025) Regorafenib exerts an inhibitory effect on the proliferation of human lung fibroblasts by reducing the production of several cytokines in vitro study. Tissue Cell 95:102876. https:\/\/doi.org\/10.1016\/j.tice.2025.102876","journal-title":"Tissue Cell"},{"key":"1612_CR72","doi-asserted-by":"publisher","first-page":"2975","DOI":"10.1158\/1078-0432.CCR-15-0020","volume":"21","author":"S Napolitano","year":"2015","unstructured":"Napolitano S, Martini G, Rinaldi B, Martinelli E, Donniacuo M, Berrino L, Vitagliano D, Morgillo F, Barra G, De Palma R, Merolla F, Ciardiello F, Troiani T (2015) Primary and acquired resistance of colorectal cancer to anti-EGFR monoclonal antibody can be overcome by combined treatment of regorafenib with cetuximab. Clin Cancer Res 21:2975\u20132983. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-0020","journal-title":"Clin Cancer Res"},{"key":"1612_CR73","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-020-2369-4","volume":"11","author":"S Niture","year":"2020","unstructured":"Niture S, Gyamfi MA, Lin M, Chimeh U, Dong X, Zheng W, Moore J, Kumar D (2020) TNFAIP8 regulates autophagy, cell steatosis, and promotes hepatocellular carcinoma cell proliferation. Cell Death Dis 11:178. https:\/\/doi.org\/10.1038\/s41419-020-2369-4","journal-title":"Cell Death Dis"},{"key":"1612_CR74","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1248\/bpb.b14-00740","volume":"38","author":"H Ohya","year":"2015","unstructured":"Ohya H, Shibayama Y, Ogura J, Narumi K, Kobayashi M, Iseki K (2015) Regorafenib is transported by the organic anion transporter 1B1 and the multidrug resistance protein 2. Biol Pharm Bull 38:582\u2013586. https:\/\/doi.org\/10.1248\/bpb.b14-00740","journal-title":"Biol Pharm Bull"},{"key":"1612_CR75","doi-asserted-by":"publisher","first-page":"2869","DOI":"10.1038\/s41388-023-02810-7","volume":"42","author":"K Okamoto","year":"2023","unstructured":"Okamoto K, Ando T, Izumi H, Kobayashi SS, Shintani T, Gutkind JS, Yanamoto S, Miyauchi M, Kajiya M (2023) AXL activates YAP through the EGFR\u2013LATS1\/2 axis and confers resistance to EGFR-targeted drugs in head and neck squamous cell carcinoma. Oncogene 42:2869\u20132877. https:\/\/doi.org\/10.1038\/s41388-023-02810-7","journal-title":"Oncogene"},{"key":"1612_CR76","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24032805","volume":"24","author":"K Oura","year":"2023","unstructured":"Oura K, Morishita A, Hamaya S, Fujita K, Masaki T (2023) The roles of epigenetic regulation and the tumor microenvironment in the mechanism of resistance to systemic therapy in hepatocellular carcinoma. Int J Mol Sci 24:2805. https:\/\/doi.org\/10.3390\/ijms24032805","journal-title":"Int J Mol Sci"},{"key":"1612_CR77","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-024-12275-w","volume":"24","author":"Y Pan","year":"2024","unstructured":"Pan Y, You B, Zhao X, Zhang S, Li W (2024) CHOP regulated by METTL14-m6A affects cell cycle arrest and regorafenib sensitivity in HCC cells. BMC Cancer 24:525. https:\/\/doi.org\/10.1186\/s12885-024-12275-w","journal-title":"BMC Cancer"},{"key":"1612_CR78","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2024.111120","volume":"118","author":"S Parimita","year":"2024","unstructured":"Parimita S, Das A, Samanta S (2024) VGLL1 stabilization of cytoplasmic TAZ promotes EGFR expression and maintains tumor initiating cells in breast cancer independent of TEAD. Cell Signal 118:111120. https:\/\/doi.org\/10.1016\/j.cellsig.2024.111120","journal-title":"Cell Signal"},{"key":"1612_CR79","doi-asserted-by":"publisher","first-page":"64447","DOI":"10.1021\/acsami.4c10363","volume":"16","author":"N Peng","year":"2024","unstructured":"Peng N, Du Y, Liu J, Li D, Li Y, Deng K, Li L, Jia P, Min J, Lin J (2024) Injectable polydopamine nanoparticle-incorporated hydrogels for antiangiogenesis and stimulating tumoricidal immunity to inhibit metastasis and recurrence postresection. ACS Appl Mater Interfaces 16:64447\u201364462. https:\/\/doi.org\/10.1021\/acsami.4c10363","journal-title":"ACS Appl Mater Interfaces"},{"key":"1612_CR80","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.101180","author":"H Qasim","year":"2026","unstructured":"Qasim H, Abu Shugaer M, Awawdeh AN, Dawaymeh T, Khattab K, Al-oweiwi M, Leoni MLG, Varrassi G (2026) Gastrointestinal stromal tumors: histopathological spectrum, molecular subtypes, and implications for targeted therapy. Cureus. https:\/\/doi.org\/10.7759\/cureus.101180","journal-title":"Cureus"},{"key":"1612_CR81","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1016\/j.trecan.2020.06.005","volume":"6","author":"V Ramesh","year":"2020","unstructured":"Ramesh V, Brabletz T, Ceppi P (2020) Targeting EMT in cancer with repurposed metabolic inhibitors. Trends Cancer 6:942\u2013950. https:\/\/doi.org\/10.1016\/j.trecan.2020.06.005","journal-title":"Trends Cancer"},{"key":"1612_CR82","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19051518","volume":"19","author":"MG Refolo","year":"2018","unstructured":"Refolo MG, Lippolis C, Carella N, Cavallini A, Messa C, D\u2019Alessandro R (2018) Chlorogenic acid improves the Regorafenib effects in human hepatocellular carcinoma cells. IJMS 19:1518. https:\/\/doi.org\/10.3390\/ijms19051518","journal-title":"IJMS"},{"key":"1612_CR83","doi-asserted-by":"publisher","DOI":"10.3390\/cells13040361","volume":"13","author":"A Repici","year":"2024","unstructured":"Repici A, Ardizzone A, De Luca F, Colarossi L, Prestifilippo A, Pizzino G, Paterniti I, Esposito E, Capra AP (2024) Signaling pathways of AXL receptor tyrosine kinase contribute to the pathogenetic mechanisms of glioblastoma. Cells 13:361. https:\/\/doi.org\/10.3390\/cells13040361","journal-title":"Cells"},{"key":"1612_CR84","doi-asserted-by":"publisher","DOI":"10.1691\/ph.2018.7988","author":"RH Rui Han","year":"2018","unstructured":"Rui Han RH, Shixin Li SL (2018) Regorafenib delays the proliferation of hepatocellular carcinoma by inducing autophagy. Pharmazie. https:\/\/doi.org\/10.1691\/ph.2018.7988","journal-title":"Pharmazie"},{"key":"1612_CR85","doi-asserted-by":"publisher","first-page":"5205","DOI":"10.21873\/anticanres.16027","volume":"42","author":"T Sasaki","year":"2022","unstructured":"Sasaki T, Shigeta K, Kitahara S, Suzuki Y, Matsui S, Seishima R, Okabayashi K, Duda DG, Kitagawa Y (2022) Inhibition of STAT3 promotes effector T cell infiltration but also immunosuppression in the HCC tumor microenvironment. Anticancer Res 42:5205\u20135215. https:\/\/doi.org\/10.21873\/anticanres.16027","journal-title":"Anticancer Res"},{"key":"1612_CR86","doi-asserted-by":"publisher","DOI":"10.1007\/s10528-025-11141-z","author":"MM Shamaa","year":"2025","unstructured":"Shamaa MM (2025) Synergistic targeting of hepatocellular carcinoma via novel Regorafenib combinations with diosmin, sulfasalazine, or rosuvastatin. Biochem Genet. https:\/\/doi.org\/10.1007\/s10528-025-11141-z","journal-title":"Biochem Genet"},{"key":"1612_CR87","doi-asserted-by":"publisher","DOI":"10.1186\/s40001-026-04075-8","author":"Q Shen","year":"2026","unstructured":"Shen Q, Wang D, Zhao Y, Hao Z, Zhang R, Song D, Tang A, Yao G, Han Q (2026) Fruquintinib potentiates the radiosensitivity of colorectal cancer by exacerbating DNA damage. Eur J Med Res. https:\/\/doi.org\/10.1186\/s40001-026-04075-8","journal-title":"Eur J Med Res"},{"key":"1612_CR88","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.00694","volume":"10","author":"W Shi","year":"2020","unstructured":"Shi W, Zhang S, Ma D, Yan D, Zhang G, Cao Y, Wang Z, Wu J, Jiang C (2020) Targeting SphK2 reverses acquired resistance of Regorafenib in hepatocellular carcinoma. Front Oncol 10:694. https:\/\/doi.org\/10.3389\/fonc.2020.00694","journal-title":"Front Oncol"},{"key":"1612_CR89","doi-asserted-by":"publisher","DOI":"10.1096\/fj.202101507RR","author":"S Sofer","year":"2022","unstructured":"Sofer S, Lamkiewicz K, Armoza Eilat S, Partouche S, Marz M, Moskovits N, Stemmer SM, Shlomai A, Sklan EH (2022) A genome-wide CRISPR activation screen reveals Hexokinase 1 as a critical factor in promoting resistance to multi-kinase inhibitors in hepatocellular carcinoma cells. FASEB J. https:\/\/doi.org\/10.1096\/fj.202101507RR","journal-title":"FASEB J"},{"key":"1612_CR90","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.90380","volume":"2","author":"V Subbiah","year":"2017","unstructured":"Subbiah V, Khawaja MR, Hong DS, Amini B, Yungfang J, Liu H, Johnson A, Schrock AB, Ali SM, Sun JX, Fabrizio D, Piha-Paul S, Fu S, Tsimberidou AM, Naing A, Janku F, Karp DD, Overman M, Eng C, Kopetz S, Meric-Bernstam F, Falchook GS (2017) First-in-human trial of multikinase VEGF inhibitor regorafenib and anti-EGFR antibody cetuximab in advanced cancer patients. JCI Insight 2:e90380. https:\/\/doi.org\/10.1172\/jci.insight.90380","journal-title":"JCI Insight"},{"key":"1612_CR91","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1038\/s41416-020-0905-8","volume":"123","author":"D Subramonian","year":"2020","unstructured":"Subramonian D, Phanhthilath N, Rinehardt H, Flynn S, Huo Y, Zhang J, Messer K, Mo Q, Huang S, Lesperance J, Zage PE (2020) Regorafenib is effective against neuroblastoma in vitro and in vivo and inhibits the RAS\/MAPK, PI3K\/Akt\/mTOR and Fos\/Jun pathways. Br J Cancer 123:568\u2013579. https:\/\/doi.org\/10.1038\/s41416-020-0905-8","journal-title":"Br J Cancer"},{"key":"1612_CR92","doi-asserted-by":"publisher","DOI":"10.1016\/j.neo.2023.100897","volume":"39","author":"H Sui","year":"2023","unstructured":"Sui H, Xiao S, Jiang S, Wu S, Lin H, Cheng L, Ye L, Zhao Q, Yu Y, Tao L, Kong F-M, Huang X, Cui R (2023) Regorafenib induces NOX5-mediated endoplasmic reticulum stress and potentiates the anti-tumor activity of cisplatin in non-small cell lung cancer cells. Neoplasia 39:100897. https:\/\/doi.org\/10.1016\/j.neo.2023.100897","journal-title":"Neoplasia"},{"key":"1612_CR93","doi-asserted-by":"publisher","DOI":"10.1038\/s41420-023-01338-9","volume":"9","author":"B Sun","year":"2023","unstructured":"Sun B, Chen H, Wang X, Chen T (2023) Regorafenib induces bim-mediated intrinsic apoptosis by blocking AKT-mediated FOXO3a nuclear export. Cell Death Discov 9:37. https:\/\/doi.org\/10.1038\/s41420-023-01338-9","journal-title":"Cell Death Discov"},{"key":"1612_CR94","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.4103\/jcrt.jcrt_2376_23","volume":"20","author":"P Sun","year":"2024","unstructured":"Sun P, Zhang Y, Tian S, Cui K, Zhong J, Zhang C, Wang D, Zhang B, Shi X, Li Z (2024) Analysis of efficacy and safety for the combination of tislelizumab and regorafenib in advanced hepatocellular carcinoma: a prospective clinical study. J Cancer Res Ther 20:1344\u20131349. https:\/\/doi.org\/10.4103\/jcrt.jcrt_2376_23","journal-title":"J Cancer Res Ther"},{"key":"1612_CR95","doi-asserted-by":"publisher","DOI":"10.3350\/cmh.2025.0972","author":"B Tao","year":"2026","unstructured":"Tao B, Yi C, Zhang B, Geng Y, Gu Y, Sun R, Wang X, Lin J, Chen J (2026) ERBB3 blockade sensitizes HCC to regorafenib after first-line TKI resistance by inhibiting HIF1A-ABCB1 signaling. CMH. https:\/\/doi.org\/10.3350\/cmh.2025.0972","journal-title":"CMH"},{"key":"1612_CR96","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1016\/j.molcel.2019.09.004","volume":"76","author":"EM Terrell","year":"2019","unstructured":"Terrell EM, Durrant DE, Ritt DA, Sealover NE, Sheffels E, Spencer-Smith R, Esposito D, Zhou Y, Hancock JF, Kortum RL, Morrison DK (2019) Distinct binding preferences between Ras and Raf family members and the impact on oncogenic Ras signaling. Mol Cell 76:872-884.e5. https:\/\/doi.org\/10.1016\/j.molcel.2019.09.004","journal-title":"Mol Cell"},{"key":"1612_CR97","doi-asserted-by":"publisher","DOI":"10.3390\/biom15010042","volume":"15","author":"Y Tian","year":"2025","unstructured":"Tian Y, Liao F, Sun H, Lei Y, Fu Y, Xia F, Wang J (2025) Effect of electric fields on the mechanical mechanism of regorafenib\u2013VEGFR2 interaction to enhance inhibition of hepatocellular carcinoma. Biomolecules 15:42. https:\/\/doi.org\/10.3390\/biom15010042","journal-title":"Biomolecules"},{"key":"1612_CR98","doi-asserted-by":"publisher","first-page":"262","DOI":"10.2152\/jmi.64.262","volume":"64","author":"C Tomida","year":"2017","unstructured":"Tomida C, Nagano H, Yamagishi N, Uchida T, Ohno A, Hirasaka K, Nikawa T, Teshima-Kondo S (2017) Regorafenib induces adaptive resistance of colorectal cancer cells via inhibition of vascular endothelial growth factor receptor. J Med Invest 64:262\u2013265. https:\/\/doi.org\/10.2152\/jmi.64.262","journal-title":"J Med Invest"},{"key":"1612_CR99","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2019.118588","volume":"569","author":"N Tsakiris","year":"2019","unstructured":"Tsakiris N, Papavasileiou M, Bozzato E, Lopes A, Vigneron AM, Pr\u00e9at V (2019) Combinational drug-loaded lipid nanocapsules for the treatment of cancer. Int J Pharm 569:118588. https:\/\/doi.org\/10.1016\/j.ijpharm.2019.118588","journal-title":"Int J Pharm"},{"key":"1612_CR100","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2023.176034","volume":"957","author":"C Ventura","year":"2023","unstructured":"Ventura C, Junco M, Santiago Valtierra FX, Gooz M, Zhiwei Y, Townsend DM, Woster PM, Maldonado EN (2023) Synergism of small molecules targeting VDAC with sorafenib, regorafenib or lenvatinib on hepatocarcinoma cell proliferation and survival. Eur J Pharmacol 957:176034. https:\/\/doi.org\/10.1016\/j.ejphar.2023.176034","journal-title":"Eur J Pharmacol"},{"key":"1612_CR101","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1256137","volume":"13","author":"Y Wan","year":"2023","unstructured":"Wan Y, Zhu H (2023) Regorafenib combined with sintilimab as second-line treatment for advanced HCC patient: a case report. Front Oncol 13:1256137. https:\/\/doi.org\/10.3389\/fonc.2023.1256137","journal-title":"Front Oncol"},{"key":"1612_CR102","doi-asserted-by":"publisher","DOI":"10.34172\/bi.32630","volume":"15","author":"Q Wang","year":"2025","unstructured":"Wang Q (2025) Targeted therapy for liver cancer: current status and future directions. Bioimpacts 15:32630. https:\/\/doi.org\/10.34172\/bi.32630","journal-title":"Bioimpacts"},{"key":"1612_CR103","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.canlet.2018.12.010","volume":"444","author":"J Wang","year":"2019","unstructured":"Wang J, Zhang N, Han Q, Lu W, Wang L, Yang D, Zheng M, Zhang Z, Liu H, Lee TH, Zhou XZ, Lu KP (2019) Pin1 inhibition reverses the acquired resistance of human hepatocellular carcinoma cells to Regorafenib via the Gli1\/Snail\/E-cadherin pathway. Cancer Lett 444:82\u201393. https:\/\/doi.org\/10.1016\/j.canlet.2018.12.010","journal-title":"Cancer Lett"},{"key":"1612_CR104","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2021.100383","volume":"2","author":"F Wang","year":"2021","unstructured":"Wang F, He M-M, Yao Y-C, Zhao X, Wang Z-Q, Jin Y, Luo H-Y, Li J-B, Wang F-H, Qiu M-Z, Lv Z-D, Wang D-S, Li Y-H, Zhang D-S, Xu R-H (2021a) Regorafenib plus toripalimab in patients with metastatic colorectal cancer: a phase Ib\/II clinical trial and gut microbiome analysis. Cell Rep Med 2:100383. https:\/\/doi.org\/10.1016\/j.xcrm.2021.100383","journal-title":"Cell Rep Med"},{"key":"1612_CR105","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.632201","volume":"12","author":"K Wang","year":"2021","unstructured":"Wang K, Yu G, Lin J, Wang Z, Lu Q, Gu C, Yang T, Liu S, Yang H (2021b) Berberine sensitizes human hepatoma cells to Regorafenib via modulating expression of circular RNAs. Front Pharmacol 12:632201. https:\/\/doi.org\/10.3389\/fphar.2021.632201","journal-title":"Front Pharmacol"},{"key":"1612_CR106","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-12606-7","volume":"10","author":"L Wei","year":"2019","unstructured":"Wei L, Lee D, Law C-T, Zhang MS, Shen J, Chin DW-C, Zhang A, Tsang FH-C, Wong CL-S, Ng IO-L, Wong CC-L, Wong C-M (2019) Genome-wide CRISPR\/Cas9 library screening identified PHGDH as a critical driver for Sorafenib resistance in HCC. Nat Commun 10:4681. https:\/\/doi.org\/10.1038\/s41467-019-12606-7","journal-title":"Nat Commun"},{"key":"1612_CR107","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2025.147514","volume":"328","author":"Y Wu","year":"2025","unstructured":"Wu Y, Diao W, Zhang X, Chen D, Yang H, Zhong L, Wu C, Li Q (2025) vtRNA1-1 drives Regorafenib resistance by sustaining cancer stemness via impaired autophagy and altered svRNA biogenesis. Int J Biol Macromol 328:147514. https:\/\/doi.org\/10.1016\/j.ijbiomac.2025.147514","journal-title":"Int J Biol Macromol"},{"key":"1612_CR108","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2147\/BCTT.S575936","volume":"18","author":"W Wu","year":"2026","unstructured":"Wu W, He Y, Zhang C (2026) Emerging targeted and multimodal therapeutic strategies in breast cancer: a comprehensive review. BCTT 18:1\u201328. https:\/\/doi.org\/10.2147\/BCTT.S575936","journal-title":"BCTT"},{"key":"1612_CR109","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23147782","volume":"23","author":"K Wuputra","year":"2022","unstructured":"Wuputra K, Hsiao P-J, Chang W-T, Wu P-H, Chen L-A, Huang J-W, Su W-L, Yang Y-H, Wu D-C, Yokoyama KK, Kuo K-K (2022) FOXM1-CD44 signaling is critical for the acquisition of Regorafenib resistance in human liver cancer cells. Int J Mol Sci 23:7782. https:\/\/doi.org\/10.3390\/ijms23147782","journal-title":"Int J Mol Sci"},{"key":"1612_CR110","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.ejpb.2023.02.016","volume":"185","author":"D Xia","year":"2023","unstructured":"Xia D, Hu C, Hou Y (2023) Regorafenib loaded self-assembled lipid-based nanocarrier for colorectal cancer treatment via lymphatic absorption. Eur J Pharm Biopharm 185:165\u2013176. https:\/\/doi.org\/10.1016\/j.ejpb.2023.02.016","journal-title":"Eur J Pharm Biopharm"},{"key":"1612_CR111","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s13053-021-00165-2","volume":"19","author":"T Xie","year":"2021","unstructured":"Xie T, Feng Q, Li Z, Lu M, Li J, Lizaso A, Xiang J, Zhang L, Shen L, Peng Z (2021) Heterogeneous constitutional mismatch repair deficiency with MSH6 missense mutation clinically benefits from pembrolizumab and regorafenib combination therapy: a case report and literature review. Hered Cancer Clin Pract 19:7. https:\/\/doi.org\/10.1186\/s13053-021-00165-2","journal-title":"Hered Cancer Clin Pract"},{"key":"1612_CR112","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.114254","volume":"159","author":"L Xie","year":"2023","unstructured":"Xie L, Liu M, Cai M, Huang W, Guo Y, Liang L, Cai W, Liu J, Liang W, Tan Y, Lai M, Lin L, Zhu K (2023) Regorafenib enhances anti-tumor efficacy of immune checkpoint inhibitor by regulating IFN-\u03b3\/NSDHL\/SREBP1\/TGF-\u03b21 axis in hepatocellular carcinoma. Biomed Pharmacother 159:114254. https:\/\/doi.org\/10.1016\/j.biopha.2023.114254","journal-title":"Biomed Pharmacother"},{"key":"1612_CR113","doi-asserted-by":"publisher","first-page":"1617401","DOI":"10.3389\/fmed.2025.1617401","volume":"12","author":"X Xu","year":"2025","unstructured":"Xu X, Li H, Li R, Xu Y, Xu YiHeng, Huang H, Lv X, Liao C, Ye J, Bo L (2025) Mechanisms and potential therapeutic targets of SphK1 and SphK2 in hepatocellular carcinoma. Front Med 12:1617401. https:\/\/doi.org\/10.3389\/fmed.2025.1617401","journal-title":"Front Med"},{"key":"1612_CR114","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s40170-023-00311-5","volume":"11","author":"H Yang","year":"2023","unstructured":"Yang H, Chen D, Wu Y, Zhou H, Diao W, Liu G, Li Q (2023) A feedback loop of PPP and PI3K\/AKT signal pathway drives regorafenib-resistance in HCC. Cancer Metab 11:27. https:\/\/doi.org\/10.1186\/s40170-023-00311-5","journal-title":"Cancer Metab"},{"key":"1612_CR115","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2406936121","volume":"121","author":"W-L Ye","year":"2024","unstructured":"Ye W-L, Huang L, Yang X-Q, Wan S, Gan W-J, Yang Y, He X-S, Liu F, Guo X, Liu Y-X, Hu G, Li X-M, Shi W-Y, He K, Wu Y-Y, Wu W-X, Lu J-H, Song Y, Qu C-J, Wu H (2024) TRIM21 induces selective autophagic degradation of c-Myc and sensitizes Regorafenib therapy in colorectal cancer. Proc Natl Acad Sci U S A 121:e2406936121. https:\/\/doi.org\/10.1073\/pnas.2406936121","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1612_CR116","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2021\/9959946","volume":"2021","author":"W Yu","year":"2021","unstructured":"Yu W, Tao Q, Zhang Y, Yi F, Feng L (2021) Efficacy and safety of Regorafenib combined with toripalimab in the third-line and beyond treatment of advanced colorectal cancer. J Oncol 2021:1\u20137. https:\/\/doi.org\/10.1155\/2021\/9959946","journal-title":"J Oncol"},{"key":"1612_CR117","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/s13046-021-01874-1","volume":"40","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, Wang D, Peng M, Tang L, Ouyang J, Xiong F, Guo C, Tang Y, Zhou Y, Liao Q, Wu X, Wang H, Yu J, Li Y, Li X, Li G, Zeng Z, Tan Y, Xiong W (2021) Single-cell RNA sequencing in cancer research. J Exp Clin Cancer Res 40:81. https:\/\/doi.org\/10.1186\/s13046-021-01874-1","journal-title":"J Exp Clin Cancer Res"},{"key":"1612_CR118","doi-asserted-by":"publisher","first-page":"424","DOI":"10.18632\/oncotarget.28602","volume":"15","author":"J Zhang","year":"2024","unstructured":"Zhang J, Zhou L, Zhao S, El-Deiry WS (2024a) Regorafenib synergizes with TAS102 against multiple gastrointestinal cancers and overcomes cancer stemness, trifluridine-induced angiogenesis, ERK1\/2 and STAT3 signaling regardless of KRAS or BRAF mutational status. Oncotarget 15:424\u2013438. https:\/\/doi.org\/10.18632\/oncotarget.28602","journal-title":"Oncotarget"},{"key":"1612_CR119","doi-asserted-by":"publisher","DOI":"10.3724\/abbs.2024058","author":"S Zhang","year":"2024","unstructured":"Zhang S, Xue X, Chen F, Yang Y, Zhang N, Chen Y, Wu W, Wang J, Zheng N (2024b) COL5A2 drives Regorafenib resistance-induced metastatic phenotype via reducing LIFR expression in hepatocellular carcinoma. ABBS. https:\/\/doi.org\/10.3724\/abbs.2024058","journal-title":"ABBS"},{"key":"1612_CR120","doi-asserted-by":"publisher","first-page":"2549","DOI":"10.21037\/jgo-23-590","volume":"14","author":"J Zhao","year":"2023","unstructured":"Zhao J, Guo Y, Feng T, Rong D, Kong X, Huang T, Lopez-Lopez V, Yarmohammadi H, Sakamoto Y, Zhu D, Yao A, Xia Y (2023) Efficacy and safety of regorafenib in combination with immune checkpoint inhibitor therapy as second-line and third-line regimen for patients with advanced hepatocellular carcinoma: a retrospective study. J Gastrointest Oncol 14:2549\u20132558. https:\/\/doi.org\/10.21037\/jgo-23-590","journal-title":"J Gastrointest Oncol"},{"key":"1612_CR121","doi-asserted-by":"publisher","DOI":"10.1016\/j.taap.2024.117042","volume":"490","author":"X Zhao","year":"2024","unstructured":"Zhao X, Zhu X, Tao H, Zou H, Cao J, Chen Y, Zhang Z, Zhu Y, Li Q, Li M (2024) Liquidambaric acid inhibits the proliferation of hepatocellular carcinoma cells by targeting PPAR\u03b1-RXR\u03b1 to down-regulate fatty acid metabolism. Toxicol Appl Pharmacol 490:117042. https:\/\/doi.org\/10.1016\/j.taap.2024.117042","journal-title":"Toxicol Appl Pharmacol"},{"key":"1612_CR122","doi-asserted-by":"publisher","first-page":"6163","DOI":"10.18632\/aging.204826","volume":"15","author":"Y Zheng","year":"2023","unstructured":"Zheng Y, Ji H, Yi W, Chen Z, Hu X, Zhou J, Wang Y, Zheng X (2023) PRMT5 facilitates angiogenesis and EMT via HIF-1\u03b1\/VEGFR\/Akt signaling axis in lung cancer. Aging Albany NY 15:6163\u20136178. https:\/\/doi.org\/10.18632\/aging.204826","journal-title":"Aging Albany NY"},{"key":"1612_CR123","doi-asserted-by":"publisher","first-page":"2401789","DOI":"10.1002\/advs.202401789","volume":"11","author":"Y Zheng","year":"2024","unstructured":"Zheng Y, Ye S, Huang S, Cheng Y, Zhang Y, Leng Y, He M, Wu E, Chen J, Kong L, Zhang H (2024) Lefamulin overcomes acquired drug resistance via regulating mitochondrial homeostasis by targeting ILF3 in hepatocellular carcinoma. Adv Sci 11:2401789. https:\/\/doi.org\/10.1002\/advs.202401789","journal-title":"Adv Sci"},{"key":"1612_CR124","doi-asserted-by":"publisher","first-page":"515","DOI":"10.7150\/jca.127381","volume":"17","author":"L Zhong","year":"2026","unstructured":"Zhong L, Li Q, Xiong T, Lin S, Wang K, Li G, Yan Y, Liu J, Xue C (2026) Spatial omics in gastrointestinal oncology: recent advances, therapeutic insights, and clinical translation. J Cancer 17:515\u2013523. https:\/\/doi.org\/10.7150\/jca.127381","journal-title":"J Cancer"},{"key":"1612_CR125","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1002\/mc.70017","volume":"64","author":"L Zhu","year":"2025","unstructured":"Zhu L, Wang W, Dong Y, Han X, Zhang W, Zhang Z, Guo W, Gu Y (2025) Venetoclax synergizes with regorafenib for colorectal cancer by targeting BCL-2. Mol Carcinog 64:1683\u20131696. https:\/\/doi.org\/10.1002\/mc.70017","journal-title":"Mol Carcinog"},{"key":"1612_CR126","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1158\/1535-7163.MCT-22-0808","volume":"22","author":"S Zitzmann-Kolbe","year":"2023","unstructured":"Zitzmann-Kolbe S, Kristian A, Zopf D, Kamfenkel C, Politz O, Ellingsen C, Hilbig J, Juul MU, Fonslet J, Nielsen CH, Schatz CA, Bjerke RM, Cuthbertson AS, Mumberg D, Hagemann UB (2023) A targeted thorium-227 conjugate demonstrates efficacy in preclinical models of acquired drug resistance and combination potential with chemotherapeutics and antiangiogenic therapies. Mol Cancer Ther 22:1073\u20131086. https:\/\/doi.org\/10.1158\/1535-7163.MCT-22-0808","journal-title":"Mol Cancer Ther"},{"key":"1612_CR127","doi-asserted-by":"publisher","first-page":"3176","DOI":"10.1002\/cam4.883","volume":"5","author":"D Zopf","year":"2016","unstructured":"Zopf D, Fichtner I, Bhargava A, Steinke W, Thierauch K, Diefenbach K, Wilhelm S, Hafner F, Gerisch M (2016) Pharmacologic activity and pharmacokinetics of metabolites of regorafenib in preclinical models. Cancer Med 5:3176\u20133185. https:\/\/doi.org\/10.1002\/cam4.883","journal-title":"Cancer Med"}],"container-title":["Archives of Pharmacal Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12272-026-01612-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12272-026-01612-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12272-026-01612-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T15:03:39Z","timestamp":1777907019000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12272-026-01612-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":127,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["1612"],"URL":"https:\/\/doi.org\/10.1007\/s12272-026-01612-1","relation":{},"ISSN":["0253-6269","1976-3786"],"issn-type":[{"value":"0253-6269","type":"print"},{"value":"1976-3786","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"13 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that there are no competing interests regarding this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}